This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXNPEC3B0CQ_M.jpg
“This new ambition does not include potential for additional sales ambition upgrade from chronic obstructive pulmonary disease (COPD), with pivotal readouts anticipated in 2023,” Sanofi said in a statement.
This month, analysts at investment bank JP Morgan had said they expected Sanofi to raise its peak sales guidance for Dupixent to about $15 billion.
Sanofi is working with British partner GlaxoSmithKline (NYSE:GSK) to develop a COVID-19 vaccine.
Sanofi also announced on Tuesday a partnership with U.S company IGM Biosciences (NASDAQ:IGMS) in the field of treatments for oncology, immunology and inflammation.
($1=0.9096 euros)
